Important note: Information in this article was accurate in 2008. The state of the art may have changed since the publication date.
Bangkok Post - May 15, 2008
Apiradee Treerutkuarkul
Of the total of 16,402 volunteers recruited for the clinical trial, 7,000 had completed the monitoring period so far. Follow-up tests found the number of volunteers who had contracted HIV/Aids while participating in the programme was lower than the expected 150-200, said chief researcher Supachai Rerks-ngarm.
The clinical trial was launched in October 2003.
Most of the volunteers contracted the virus through unprotected sex. But the low infection rate among the volunteers could not give a complete indication of how effective the vaccine was in Aids prevention.
"It is still too early to say for the time being if the vaccine is effective. However, it is likely the results of the clinical trial will be ready in July 2009," he said.
Assistant chief researcher Nakorn Premsri said the programme would be responsible for providing funds for medication for those volunteers who had contracted the virus during their participation in the trial.
Funded by pharmaceutical firms and health advocacy groups in the United States along with the Public Health Ministry, the project faced a stumbling block initially due to a shortage of volunteers. It took a long time before all the planned 16,000 volunteers were recruited.
All volunteers aged 20 to 30 live in the two eastern provinces of Rayong and Chon Buri where the rate of infection among labourers is high.
Half of them have been getting injections of two combination vaccines - the canary pox vaccine Alvac and a synthesised combination of the B and E sub-types of the Aids virus AidsVax, with the rest getting placebo injections over a one-year period.
Each volunteer would be monitored for at least another three and a half years.
The clinical trial in Thailand was the first time the two vaccines were combined as experts believed that the combination was an effective alternative to HIV/Aids control.
Previously, research projects in Africa had used only one vaccine at a time and the results were unsatisfactory.
080515
BP080503
Copyright © 2008 - The Bangkok Post. Reproduction of this article (other than one copy for personal reference) must be cleared through the Bangkok Post.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .